Recruiting
Pancreatic carcinoma metastatic
RecruitingStudy of Ginisortamab with Nab-Paclitaxel and Gemcitabine or MEK Inhibitor for Patients with Metastatic Pancreatic Cancer
Registered drugNo placebo
Study of Ginisortamab with Nab-Paclitaxel and Gemcitabine or MEK Inhibitor for Patients with Metastatic Pancreatic Cancer
Registered drugNo placebo
- Disease:Pancreatic carcinoma metastatic
- Substances:CobimetinibGinisortamab
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Cobimetinib


